Proteros biostructures GmbH

Proteros biostructures and Orion Pharma agree on long-term multi-target collaboration including assembly of a joint novel and unique HTS small-molecule library with full chemistry support of Enamine

Proteros receives minority investment from private equity firm Inflexion

Proteros and Adrestia initiate multi-target partnership to discover first-in-class drugs for intractable genetic diseases

Proteros, co-founder of Rodin Therapeutics, announces Rodin’s acquisition by Alkermes

Proteros biostructures GmbH names Dave Lemus as new executive board member

Proteros enters into new research collaboration with Johnson & Johnson Innovation on sub-class of epigenetic targets